An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants

Prophylactic vaccines against SARS-CoV-2 have been extensively developed globally to overcome the COVID-19 pandemic. However, recently emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 limit the vaccine protection effects and successfully escape antibody cocktail treatment. Herein, based on our previously engineered adeno-associated viral (AAV) vector, AAV-ie, and systematic immunogen screening, we developed an AAV-ie-S1 vaccine with thermostability, high efficiency, safety, and single-dose vaccination advantage. Importantly, the AAV-ie-S1 immune sera efficiently neutralize B.1.1.7 and B.1.351, indicating a potential to circumvent the spreading of SARS-CoV-2. ### Competing Interest Statement A patent based on this study has been submitted. The patent applicant is ShanghaiTech University and all authors are listed as inventors. The AAV-ie vector has been patented, the application NO. is CN201910807643.X.